San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium

January 13, 2017
1 min read

10 takeaways from San Antonio Breast Cancer Symposium

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The San Antonio Breast Cancer Symposium featured updates in experimental biology, etiology, prevention, diagnosis and treatment of breast cancer.

HemOnc Today presents 10 takeaways from the symposium that may affect your practice.

  • The addition of estrogen deprivation to neoadjuvant chemotherapy did not significantly increase pathologic complete response rate among patients with hormone receptor–positive, HER-2–positive breast cancer. Read more.
  • Sentinel lymph node biopsy during surgery that identified no evidence of cancer appeared associated with low risk for recurrence in axillary lymph nodes among certain patients with early-stage breast cancer, according to follow-up results of the GANEA 2 trial. Read more.
  • The extended use of letrozole conferred no survival benefit to postmenopausal women with hormone receptor–positive breast cancer, Terry P. Mamounas, MD, MPH, FACS, from UF Health Cancer Center at Orlando Health, told HemOnc Today. Watch here.
  • A scalp-cooling system effectively and safely prevented hair loss in more than half of patients with breast cancer who received chemotherapy, according to results of the SCALP trial. Read more.
  • Postmenopausal women with breast cancer treated with aromatase inhibitors demonstrated reduced endothelial function compared with healthy controls. Read more.
  • Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh and a HemOnc Today Editorial Board member, spoke with HemOnc Today about the potential impact of the NSABP B-52 trial. Watch here.
  • The addition of ibandronate to adjuvant hormonal therapy demonstrated no proof of benefit for postmenopausal women with early hormone receptor–positive breast cancer, according to results of the TEAM IIb trial. Read more.
  • The addition of pertuzumab (Perjeta, Genentech) to trastuzumab (Herceptin, Genentech) plus an aromatase inhibitor appeared well tolerated and prolonged PFS in postmenopausal women with HER-2–positive locally advanced or metastatic breast cancer, according to results of the phase 2 PERTAIN trial. Read more.
  • Amy J. Irwin, MD, medical oncologist with Virginia Cancer Specialists, a practice in The US Oncology Network, provides an overview of what she considered the key themes from the symposium. Watch here.
  • Women who experienced certain menopausal symptoms appeared significantly less likely to adhere to long-term breast cancer therapy, according to data from the IBIS-I study. Read more.